You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

494 Results
Guidelines and Advice
Drug
Other Name(s): Alecensaro®
Nov 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Funding:
Exceptional Access Program
    alectinib - Adjuvant treatment of ALK-positive non-small cell lung cancer, according to specific criteria
Nov 2025
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    anastrozole
New
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Funding:
New Drug Funding Program
    Nivolumab - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma
Updated
Dec 2025
Document
This hub contains tools and resources for primary care providers, colposcopists and other health care providers. This material supports the Ontario...
Drug
Other Name(s): Rybrevant®
Updated
Dec 2025
Guidelines and Advice
Status: Current
Version: 1
Updated
Nov 2025

Pages